![](/img/cover-not-exists.png)
Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease
Gevers, Tom JG, Chrispijn, Melissa, Wetzels, Jack FM, Drenth, Joost PHVolume:
13
Language:
english
Journal:
BMC Nephrology
DOI:
10.1186/1471-2369-13-17
Date:
December, 2012
File:
PDF, 164 KB
english, 2012